NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, specifically targeting low-density lipoprotein cholesterol (LDL-C) lowering. The company's lead product candidate, obicetrapib, is an oral, highly selective cholesteryl ester transfer protein (CETP) inhibitor intended as an adjunct to statin therapy for patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. NewAmsterdam is also investigating obicetrapib in combination with ezetimibe and exploring its potential role in mitigating Alzheimer’s disease risk. The company holds exclusive rights to obicetrapib, which it acquired from a subsidiary of Amgen, and has partnered with Menarini to commercialize the drug in Europe under the brand names Ubeslo and Evlarco. NewAmsterdam plans to commercialize obicetrapib in the United States independently and is pursuing regulatory approvals in the UK, Switzerland, and other jurisdictions. The company was co-founded by lipidologist John Kastelein and venture capital firm Forbion, and it lists on the Nasdaq.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage newamsterdampharma.com
Sector Healthcare IR page ir.newamsterdampharma.com
Tags
cardiovascular disease, lipid-lowering, cetp inhibitors, ldl-c reduction, alzheimer's disease, fixed-dose combinations, oral therapeutics, clinical trials, obicetrapib, Ubeslo, Evlarco, Menarini, ezetimibe, BROADWAY, BROOKLYN, TANDEM, PREVAIL, TULIP, ROSE, OCEAN, ROSE2, SPINOZA, Amgen, Forbion
Press page —

Metrics

Valuation  
Market cap $ 2.914B
Market cap (USD) $ 2.914B
P/E -14.48
PEG —
P/BV 4.62
P/S 112.35
P/OCF -19.37
P/FCF -19.32
Dividend yield —
Turnover / mcap —
Returns  
ROE -28.3%
ROI -105.3%
ROIC -87.5%
Profit margin -905.7%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 54
Quality score -81.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 22.503M 45.563M 14.09M 98.179M 0
Net profit -203.819M -241.598M -176.937M -78.595K -41.785M
Free cash flow -148.029M -159.236M -141.242M 8.014M -29.536M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 35.08 25.7 11.17 10.9 —
Price performance 12m 0.36 1.3 0.02 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 126,000 60,000 448,000 202,000
Cash and deposits (USD) — — — 340M 772M 490M
Right-of-use assets (USD) — — 120,000 55,000 431,000 185,000
Cash flow detail
Operating cash flow (USD) — -29.5M 10.7M -141M -159M -148M
Purchases of property, plant and equipment (USD) — -24,000 -221,000 -24,000 -672,000 -246,000
Change in payables (cash effect) (USD) — 6.56M 4.81M 5.07M -12.9M 4.91M
Interest paid (cash effect) (USD) — — -277,000 — — —
Income taxes paid (cash effect) (USD) — — — -27,000 -1,000 —
Share-based compensation (USD) — 1.24M 4.12M 24.6M 33.6M 59.4M
Free cash flow (OCF - PPE - intangibles) (USD) — -29.5M 10.4M -141M -159M -148M
Income detail
Research and development expense (EUR) 4.05M 25M 82.2M 159M 151M 142M
Total comprehensive income (USD) — -41.5M -11.5M -177M -242M -203M
Comprehensive income to owners (USD) — -41.5M -11.5M -177M -242M -203M
Reported Mar 31, 2023 Feb 28, 2024 Feb 28, 2024 Feb 26, 2025 Feb 26, 2025 Feb 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 4, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto.

Additionally, the information contained in Item 2.02, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms-

- The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures-

NAARDEN, the Netherlands and MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the dosing of the first participant in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease.

"The first participant dosed in SPINOZA marks an important milestone for NewAmsterdam as we expand the clinical evaluation of obicetrapib in Alzheimer's disease," said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. "Alzheimer's disease pathology typically begins years before clinical symptom onset, creating an opportunity for intervention. The commencement of this trial is an important step in our effort to understand whether obicetrapib may affect biological changes associated with the disease before noticeable symptoms develop. The findings from our BROADWAY Alzheimer’s disease biomarker analysis, together with the growing body of evidence linking lipid metabolism to Alzheimer's disease pathology, provide a strong scientific rationale for further evaluating the effect of obicetrapib on biomarkers associated with disease progression and neurodegeneration."

SPINOZA is a Phase 2b, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of obicetrapib in approximately 400 participants with preclinical Alzheimer's disease. Eligible participants have biomarker evidence consistent with early Alzheimer's disease pathology and carry ApoE4/E4, ApoE3/E4 or ApoE3/E3 genotypes. Participants will be randomized 1:1, stratified by genotype, to receive obicetrapib 10 mg or placebo for 52 weeks. Following completion of the double-blind treatment period, participants may enter a 26-week open-label extension study during which all participants will receive obicetrapib.

The SPINOZA trial design was informed by findings from the prespecified Alzheimer’s disease biomarker analysis in the Company’s Phase 3 BROADWAY trial, which demonstrated the strongest observed biomarker response in ApoE4/E4 participants and supportive signals across additional genotype-defined populations. These findings informed the genotype-stratified design of SPINOZA and the selection of enrollment criteria intended to further evaluate the effects of obicetrapib on biomarkers associated with Alzheimer's disease pathology and neurodegeneration. SPINOZA further expands NewAmsterdam's clinical development program for obicetrapib alongside its ongoing Phase 3 REMBRANDT, RUBENS and PREVAIL clinical trials.

People interested in learning more about the SPINOZA trial can visit spinoza.longboat.com

. Additional eligibility criteria apply, and eligibility can only be determined by the study team following the required screening assessments.

About Obicetrapib

Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About the Phase 2b SPINOZA Trial

The SPINOZA trial is a Phase 2b, randomized, double-blind, placebo-controlled, parallel-group study evaluating the effect of obicetrapib on plasma p-tau217 and other biomarkers associated with Alzheimer’s disease pathology and neurodegeneration in approximately 400 participants with preclinical Alzheimer's disease.

Eligible participants are adults aged 55 to 85 years with preclinical Alzheimer's disease (Stage 1 or Stage 2) as defined by FDA guidance for Early Alzheimer's Disease drug development, a Mini-Mental State Examination (MMSE) score of at least 27, a global Clinical Dementia Rating (CDR) score of 0.5 or lower, and biomarker evidence of Alzheimer's disease pathology. Enrollment is restricted to participants with ApoE4/E4, ApoE3/E4, or ApoE3/E3 genotypes. Participants will be randomized 1:1 to receive obicetrapib 10 mg or placebo, stratified by genotype.

The primary efficacy endpoint is change from baseline to Week 52 in plasma phosphorylated tau 217 (p-tau217), a biomarker associated with Alzheimer’s disease pathology. Secondary endpoints include changes in plasma Alzheimer's disease biomarkers, including Aβ42/Aβ40, p-tau217/Aβ42, p-tau217/Aβ42/40 and BD-tau, as well as change from baseline to Week 52 in the Preclinical Alzheimer's Cognitive Composite 5 (PACC5) score.

Following completion of the 52-week double-blind treatment period, eligible participants may choose to enter an open-label extension lasting at least 26 weeks, during which all participants will receive obicetrapib.

BROADWAY Alzheimer’s Analysis

In BROADWAY, a pre-specified analysis was designed to assess plasma biomarkers of Alzheimer’s disease in patients enrolled in the BROADWAY trial and evaluated the effects of longer duration of therapy (12 months) with a prespecified ApoE population, based on phenotypic analysis. The analysis included 1,535 patients, including 367 ApoE4 carriers (ApoE3/E4 or ApoE4/E4), whose ApoE status was able to be determined. Because this analysis was based on a subset of patients from BROADWAY (which was designed to evaluate LDL-C reductions in an ASCVD and/or HeFH population), the AD analysis was not controlled for baseline differences between the treatment and placebo populations, but statistical analyses were adjusted for baseline biomarker values and age. The absolute and percent change over 12 months in p-tau217, a key biomarker of AD pathology, was measured among patients with baseline and end of study datapoints above the lower limit of quantitation. Additional outcome measures included NFL, GFAP, p-tau181, and Aβ42/40 ratio absolute and percent change over 12 months. NewAmsterdam observed statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full analysis set (p=0.025; n= 1,535) and in ApoE4 carriers (p=0.022; n=367) as well as favorable trends in the other AD biomarkers. Although a safety analysis was not performed in the AD analysis population, in BROADWAY obicetrapib was observed to be well-tolerated, with safety results comparable to placebo.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to building a new standard of care for people living with cardiometabolic and neurodegenerative diseases. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.

NewAmsterdam Pharma Company N.V. — Other Events Bull 7 Bear 0 Clinical/regulatory

Other Events.

On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination, or “FDC”) for patients with primary hypercholesterolaemia (heterozygous familial (“HeFH”) and non-familial) or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide. The authorizations apply across all EU Member States, as well as Iceland, Liechtenstein and Norway.

Prompts

NewAmsterdam Pharma Company N.V. (ticker NAMS), listed in United States.

Company History

Date Change Detail
Dec 31, 2023 Reporting currency Its US reports are in USD instead of EUR from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

ETFs Holding NewAmsterdam Pharma Company N.V.

ETF Weight in ETF Shares Market value As of
DRKY 3.12% 28,007 $ 545.016K Nov 17, 2026
CGMM 0.42% 787,035 $ 15.316M Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
NAMS canonical Common share — US nasdaq 24.32 USD 2026-09-30
NAMSW Warrant — US nasdaq 12.65 USD 2026-09-30